Dr. John Cush RheumNow
3 years 3 months ago
82 Patients with Knee OA and Severe Obesity, showed that Bariatric Surgery and Weight Loss Before TKA significantly Reduced Complications Versus TKA Alone (without Wt loss surgery). TKA was delayed 17 (vs 4 mos) in Wt loss group.https://t.co/JR3BUqthhy https://t.co/q93AI4cpK0
Dr. John Cush RheumNow
3 years 3 months ago
In 2020, there were 619 million back pain cases Worldwide; this is expected to grown by 50% to 843 million people by 2050, due to ageing of populations.
https://t.co/ruB0gfMoFm https://t.co/UATKXRVj9p
Dr. John Cush RheumNow
3 years 3 months ago
82 Patients with Knee OA and Severe Obesity, showed that Bariatric Surgery and Weight Loss Before TKA significantly Reduced Complications Versus TKA Alone (without Wt loss surgery). TKA was delayed 17 (vs 4 mos) in Wt loss group.https://t.co/JR3BUqthhy https://t.co/mUh5FfSUBR
Nephrology Dialysis Transplantation has published an overview of the management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis based on several international guidelines, including those frorm the ACR 2021, EULAR 2022 and KDIGO 2021 (Kidney Disease: Improving Global Outcomes).
Dr. John Cush RheumNow
3 years 3 months ago
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/DwU7L9A58i https://t.co/zeeiciPx01
Dr. John Cush RheumNow
3 years 3 months ago
Dr. Spiera's approach to PMR treatment
- prefers methylprednisolone
- rapid taper over 16 weeks
- consider GC sparing therapy (MTX, IL-6i)
@Rheumnow #RNL2023 https://t.co/EtlDZm1RSb https://t.co/cZSYwYRKNM
Dr. John Cush RheumNow
3 years 3 months ago
IL-6 for PMR
SPARE and SEMAPORE (Toci), SAPHYR (Sari)
2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off
Robert Spiera @RheumNow #RNL2023 https://t.co/gpBYXhguaV https://t.co/7tU1VBUb6F
Dr. John Cush RheumNow
3 years 3 months ago
Cochrane metanalysis of antidepressant use in managing chronic pain shows they dont work, with the small exception, duloxetine - at standard dose (60 mg) it was effective, but no benefit to using a higher doses https://t.co/SReueTu4VV https://t.co/ki0snBMS3z
Dr. John Cush RheumNow
3 years 3 months ago
"Ideally, you should get your TA biopsies within 2 weeks, but that's not always possible. Don't delay tx." @anisha_dua reminds us that bx can still be positive up to 8 weeks after steroid initiation. Just be aware of lesional changes with time. #RNL2023 https://t.co/uYBNrGzdQm https://t.co/Rvs0ewHzwb
Dr. John Cush RheumNow
3 years 3 months ago
Allergic Drug - Induced Arthritis
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
https://t.co/AmpWG2Siii https://t.co/PwEgVHfDu8
Dr. John Cush RheumNow
3 years 3 months ago
MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor
A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.
https://t.co/xGPSA2oRis https://t.co/y7M42DlM7d
The second day of RheumNow Live 2023 held in March ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
Dr. John Cush RheumNow
3 years 3 months ago
Brepocitinib in Active PsA
Brepocitinib is a novel tyrosine kinase 2/JAK1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.
https://t.co/qzOVsLMkYe https://t.co/ouLyB131r8
Dr. John Cush RheumNow
3 years 3 months ago
QD Clinic - Audience Vasculitis Questions from RNL23
Audience questions from the live RNL 2023 meeting and the session on EVOLUTION AND ADVANCES IN VASCULITIS held on March 18, 2023.
https://t.co/mvimbucTnd https://t.co/uJzkZcbNLa
